编者按：RB1阴性肿瘤中核γ-微管蛋白的治疗靶点。

IF 4.1 2区医学 Q2 CELL BIOLOGY

Molecular Cancer Research Pub Date : 2024-11-01 DOI:10.1158/1541-7786.MCR-24-0792

Lisa Lindström, Bruno O Villoutreix, Sophie Lehn, Rebecka Hellsten, Elise Nilsson, Enisa Crneta, Roger Olsson, Maria Alvarado-Kristensson

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Editor's Note: Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Molecular Cancer Research 医学-细胞生物学

CiteScore

9.90

自引率

0.00%

发文量

280

审稿时长

4-8 weeks

期刊介绍： Molecular Cancer Research publishes articles describing novel basic cancer research discoveries of broad interest to the field. Studies must be of demonstrated significance, and the journal prioritizes analyses performed at the molecular and cellular level that reveal novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression. Areas of emphasis include all cancer-associated pathways (including cell-cycle regulation; cell death; chromatin regulation; DNA damage and repair; gene and RNA regulation; genomics; oncogenes and tumor suppressors; signal transduction; and tumor microenvironment), in addition to studies describing new molecular mechanisms and interactions that support cancer phenotypes. For full consideration, primary research submissions must provide significant novel insight into existing pathway functions or address new hypotheses associated with cancer-relevant biologic questions.